Reduction in Share Capital, Reverse-Stock Split Approved by Epigenomics Shareholders

Jun 29, 2011

NEW YORK (GenomeWeb News) – Epigenomics said this week that its shareholders have approved a reduction of the firm's share capital and a five-for-one reverse-stock split.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Pushback on Mosquito Paper

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

DNA for Attorneys

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Wheat Over Time

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

Cell Presents Reptilian Model for Gene Editing, Melanoma Proteomics, More

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.

Featured White Papers

Delivering Precision Health: the Role of Molecular Diagnostics

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Oct

10

Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct

21

Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu